MML Investors Services LLC Has $225,000 Stock Position in AtriCure, Inc. (NASDAQ:ATRC)

MML Investors Services LLC cut its holdings in AtriCure, Inc. (NASDAQ:ATRC) by 14.8% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,029 shares of the medical device company’s stock after selling 1,392 shares during the quarter. MML Investors Services LLC’s holdings in AtriCure were worth $225,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Panagora Asset Management Inc. lifted its holdings in shares of AtriCure by 8.2% in the second quarter. Panagora Asset Management Inc. now owns 309,547 shares of the medical device company’s stock worth $7,048,000 after acquiring an additional 23,436 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in AtriCure by 0.8% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 380,720 shares of the medical device company’s stock worth $8,669,000 after purchasing an additional 2,898 shares in the last quarter. Rhumbline Advisers lifted its stake in AtriCure by 3.7% in the 2nd quarter. Rhumbline Advisers now owns 72,936 shares of the medical device company’s stock valued at $1,661,000 after purchasing an additional 2,577 shares during the last quarter. Fiera Capital Corp boosted its position in AtriCure by 1.1% in the second quarter. Fiera Capital Corp now owns 918,207 shares of the medical device company’s stock valued at $20,908,000 after buying an additional 10,432 shares in the last quarter. Finally, Arizona State Retirement System boosted its position in AtriCure by 4.0% in the second quarter. Arizona State Retirement System now owns 13,542 shares of the medical device company’s stock valued at $308,000 after buying an additional 517 shares in the last quarter. Institutional investors own 99.11% of the company’s stock.

AtriCure Price Performance

AtriCure stock opened at $30.75 on Friday. The firm has a market cap of $1.50 billion, a P/E ratio of -37.05 and a beta of 1.40. The stock’s 50 day moving average is $33.41 and its 200 day moving average is $27.68. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.62 and a quick ratio of 2.59. AtriCure, Inc. has a one year low of $18.94 and a one year high of $39.04.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings data on Tuesday, October 29th. The medical device company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.02. AtriCure had a negative net margin of 8.70% and a negative return on equity of 8.12%. The company had revenue of $115.91 million for the quarter, compared to analyst estimates of $112.23 million. During the same period in the prior year, the firm posted ($0.20) EPS. The company’s quarterly revenue was up 17.9% on a year-over-year basis. As a group, research analysts expect that AtriCure, Inc. will post -0.72 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $40.00 price target on shares of AtriCure in a research note on Tuesday, December 17th. StockNews.com raised AtriCure from a “sell” rating to a “hold” rating in a report on Saturday, September 14th. Oppenheimer lifted their price target on AtriCure from $32.00 to $36.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. UBS Group upped their price objective on AtriCure from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Finally, Needham & Company LLC lifted their target price on shares of AtriCure from $34.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, AtriCure has a consensus rating of “Moderate Buy” and a consensus price target of $42.00.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.